	US 12,263,205 B2
	Methods of improving anemias by combining agents
Stefano Rivella, Philadelphia, PA (US); and Carla Casu, Philadelphia, PA (US)
Assigned to THE CHILDREN'S HOSPITAL OF PHILADELPHIA, Philadelphia, PA (US)
Appl. No. 17/049,050
Filed by The Children's Hospital of Philadelphia, Philadelphia, PA (US)
PCT Filed Apr. 30, 2019, PCT No. PCT/US2019/029794 § 371(c)(1), (2) Date Oct. 20, 2020, PCT Pub. No. WO2019/213016, PCT Pub. Date Nov. 7, 2019.
Claims priority of provisional application 62/664,327, filed on Apr. 30, 2018.
Prior Publication US 2021/0252106 A1, Aug. 19, 2021
Int. Cl. A61K 38/18 (2006.01); A61K 35/33 (2015.01); A61K 38/17 (2006.01); A61P 7/06 (2006.01); C12N 15/113 (2010.01)

CPC A61K 38/1816 (2013.01) [A61K 35/33 (2013.01); A61K 38/1793 (2013.01); A61P 7/06 (2018.01); C12N 15/1138 (2013.01); C12N 2310/11 (2013.01); C12N 2310/341 (2013.01); C12N 2310/351 (2013.01)]

26 Claims

1. A method for treating or inhibiting an anemia comprising administering an erythropoiesis stimulating agent (ESA) and an iron restrictive agent (IRA) to a subject having or at risk of having an anemia, wherein said IRA is a TMPRSS6 inhibitor, and wherein said TMPRSS6 inhibitor is an antisense compound, siRNA, or shRNA.